Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [HER2mouse upfront RNAseq]

ABSTRACT: We treated tumour-bearing MMTV-rtTA/tetO-HER2 female mice with either vehicle (veh), INX-315 (INX), Abemaciclib (LY) or both INX-315 and Abema in combination (LY.INX) for 7 days. Resistant tumors were collected and RNA sequencing performed

ORGANISM(S): Mus musculus

PROVIDER: GSE243149 | GEO | 2023/11/22

REPOSITORIES: GEO